

Natural-Based Nutraceuticals Targeting the Gut-Brain Axis

Prachi V Jadhav¹, Prof.Shital R Kalekar¹, Rutuja K Mhaske¹, Ayaan A Sheikh¹

¹D Y Patil University, School of Pharmacy, Ambi, TalegaonDabhade , Pune, Maharashtra, India- 410507

✉ **Corresponding author:** kalekar15shital@gmail.com

Doi: <https://doi.org/10.5281/zenodo.22301438>

Received: 8 July 2026

Accepted: 18 July 2026

Abstract

The gut-brain axis (GBA) represents a bidirectional communication network linking the gastrointestinal tract and central nervous system through neural, endocrine, immune, and metabolic pathways. Emerging evidence demonstrates that gut dysbiosis, visceral hypersensitivity, and intestinal barrier dysfunction play pivotal roles in IBS pathophysiology. This review comprehensively examines natural-based nutraceuticals from plant, marine, mineral, and animal sources that modulate the GBA and offer therapeutic potential for IBS management. Plant-derived nutraceuticals including probiotics, prebiotics, berberine, curcumin, and ginger demonstrate significant promise in modulating gut microbiota composition, enhancing short-chain fatty acid production, and reducing visceral hypersensitivity. Marine-derived omega-3 fatty acids and seaweed bioactive compounds exhibit potent anti-inflammatory and neuroprotective properties. Essential minerals including magnesium, zinc, and vitamin D address common micronutrient deficiencies while supporting intestinal barrier integrity and neural function. Animal-derived compounds such as bovine colostrum and L-glutamine contribute to mucosal healing and immune modulation. This review synthesizes current clinical evidence, elucidates mechanistic pathways, and examines commercially available formulations, providing a foundation for evidence-based nutraceutical interventions targeting the GBA in IBS management.

Keywords:gut-brain axis, irritable bowel syndrome, nutraceuticals, probiotics, omega-3 fatty acids, berberine, short-chain fatty acids, gut microbiota

1. Introduction

Irritable bowel syndrome (IBS) stands as one of the most prevalent functional gastrointestinal disorders worldwide, affecting an estimated 11% of the global population with substantial variation across geographic regions [1]. Characterized by recurrent abdominal pain associated with altered bowel habits including diarrhea, constipation, or mixed presentations, IBS significantly impairs quality of life and imposes considerable economic burden through healthcare utilization and lost productivity [2]. Despite its high prevalence, the pathophysiology of IBS remains incompletely understood, with current evidence supporting a multifactorial etiology encompassing gut dysbiosis, visceral hypersensitivity, intestinal barrier dysfunction, abnormal gut motility, and psychosocial factors [3].

The gut-brain axis (GBA) represents a sophisticated bidirectional communication network that integrates the central nervous system (CNS), enteric nervous system (ENS), autonomic nervous system, hypothalamic-pituitary-

adrenal (HPA) axis, and the gut microbiota [4]. This complex interplay occurs through neural pathways primarily via the vagus nerve, endocrine signaling through gut hormones, immune-mediated cytokine transmission, and metabolic communication through microbial metabolites including short-chain fatty acids (SCFAs) and tryptophan derivatives [5]. In IBS, disruption of this axis manifests as altered gut motility, enhanced visceral pain perception, and concurrent psychological symptoms including anxiety and depression, which affect up to 50% of patients [6].

Conventional pharmacological treatments for IBS including antispasmodics, laxatives, antidiarrheals, and low-dose tricyclic antidepressants provide symptomatic relief for many patients but are often limited by adverse effects, incomplete efficacy, and failure to address underlying pathophysiological mechanisms [7]. This therapeutic gap has catalyzed growing interest in natural-based nutraceuticals, bioactive compounds derived from food sources that confer health benefits beyond basic nutrition. These compounds offer multimodal mechanisms of action targeting the GBA, including microbiota modulation, barrier restoration, anti-inflammatory effects, and neuromodulation [8]. This review comprehensively examines the therapeutic potential of plant, marine, mineral, and animal-derived nutraceuticals in targeting the GBA for IBS management.

2. The Gut-Brain Axis in IBS Pathophysiology

The GBA operates through multiple interconnected pathways that become dysregulated in IBS. Neural communication primarily occurs via the vagus nerve, which transmits afferent signals from intestinal mechanoreceptors, chemoreceptors, and immune cells to the brainstem and higher CNS centers [9]. Efferent vagal signals modulate gut motility, secretion, and immune function through the cholinergic anti-inflammatory pathway. Enterochromaffin cells within the intestinal epithelium synthesize over 90% of the body's serotonin, playing a critical role in regulating gut motility and visceral sensitivity [10]. Tryptophan metabolism represents another crucial pathway, with gut microbiota influencing the balance between serotonin synthesis and kynurenine degradation, thereby impacting both intestinal function and mood regulation [11].

Microbial metabolites serve as essential signaling molecules within the GBA. SCFAs, primarily acetate, propionate, and butyrate, are produced through bacterial fermentation of dietary fibers and exert profound effects on gut barrier integrity, immune modulation, and neural function [12]. Butyrate, in particular, serves as the primary energy source for colonocytes, upregulates tight junction proteins including occludin and claudin-1, and attenuates visceral hypersensitivity through multiple receptor-mediated pathways [13]. Meta-analytic evidence indicates that alterations in fecal SCFA profiles correlate with IBS symptom severity, with propionate emerging as a potential biomarker for diarrhea-predominant IBS [14].




Figure 1: The Gut-Brain Axis in IBS and modulation by natural-based nutraceuticals from plant, marine, mineral, and animal sources

1. Plant-Based Nutraceuticals

1.1 Probiotics and Prebiotics

Probiotics, defined as live microorganisms conferring health benefits when consumed in adequate amounts, represent the most extensively studied nutraceutical intervention for IBS. An umbrella review of 27 systematic reviews demonstrated that probiotics, particularly strains from *Lactobacillus* and *Bifidobacterium* genera, produce modest but statistically significant reductions in global IBS symptoms, abdominal pain, and bloating, with numbers needed to treat ranging from 4 to 7 [15]. Multi-strain formulations including VSL#3 and specific combinations such as *Bifidobacterium longum* with *Lactobacillus rhamnosus* demonstrate superior efficacy compared to single-strain products [16]. Mechanistically, probiotics modulate the GBA through enhancement of SCFA production, preservation of tight junction integrity, attenuation of pro-inflammatory cytokines including TNF-alpha and IL-6, and modulation of tryptophan metabolism [17].

Prebiotics, non-digestible substrates selectively utilized by beneficial gut microorganisms, complement probiotic therapy by promoting endogenous SCFA production. Inulin, fructo-oligosaccharides (FOS), and galacto-oligosaccharides (GOS) have demonstrated capacity to increase *Bifidobacterium* abundance and enhance butyrate production [18]. Partially hydrolyzed guar gum (PHGG) exhibits particularly favorable tolerability in

clinical trials showing significant relief from bloating symptoms at doses of 6 grams daily [19]. Synbiotic combinations, pairing probiotics with prebiotics, offer synergistic benefits by enhancing microbial colonization and metabolic activity [20].

1.2 Herbal Bioactive Compounds

Berberine, an isoquinoline alkaloid derived from Berberidaceae plants, has emerged as a potent modulator of the GBA with particular relevance to IBS. Clinical and preclinical studies demonstrate that berberine promotes beneficial bacteria including *Bacteroides*, *Bifidobacterium*, and *Lactobacillus* while suppressing pathogenic *Escherichia coli* [21]. In IBS models, berberine nanoparticles reduced visceral hypersensitivity and diarrhea through modulation of serotonin, vasoactive intestinal peptide, and NF-kappaB signaling pathways [22]. Berberine additionally enhances intestinal epithelial barrier function by upregulating tight junction proteins and reducing intestinal permeability [23].

Curcumin, the primary bioactive constituent of turmeric (*Curcuma longa*), exhibits multimodal GBA-modulating properties through antioxidant, anti-inflammatory, and neuromodulatory mechanisms. In IBS rat models, curcumin significantly reduced abdominal withdrawal reflex scores while increasing hippocampal serotonin, brain-derived neurotrophic factor (BDNF), and cAMP response element-binding protein (pCREB) [24]. Clinical studies demonstrate that curcumin supplementation at 500 mg daily significantly reduces anxiety scores and gastrointestinal symptom rating scale scores in patients with functional digestive complaints [25]. Formulations combining curcumin with essential fennel oil improved IBS severity indices and quality of life measures across diverse patient populations [26].

Ginger (*Zingiber officinale*) has been traditionally utilized for gastrointestinal complaints across multiple medical systems. Its active constituents, gingerol and shogaol, modulate gut motility through muscarinic receptor activation and serotonin pathways while exerting potent anti-inflammatory effects [27]. Clinical trials indicate that ginger accelerates gastric emptying and reduces symptoms of functional dyspepsia, with doses of 1000-2000 mg daily demonstrating efficacy in reducing nausea, bloating, and abdominal discomfort [28]. These mechanisms position ginger as a valuable adjunctive therapy for IBS symptom management.

1.3 Polyphenols and the Gut-Brain Axis

Dietary polyphenols have emerged as promising modulators of the GBA through reciprocal interactions with the intestinal microbiota [54]. Because many polyphenols are poorly absorbed

in the small intestine, substantial amounts reach the colon, where resident microbes metabolize them into smaller phenolic derivatives with improved bioavailability and bioactivity [55]. In parallel, polyphenols selectively promote beneficial taxa such as *Bifidobacterium*, *Lactobacillus*, and *Akkermansia* along with other SCFA-producing bacteria, while suppressing inflammatory or pathogenic microbes, thereby reshaping intestinal ecology and metabolite production [56].

These microbial shifts are associated with enhanced SCFA production, improved tight junction integrity, reduced lipopolysaccharide-driven inflammation, and modulation of neurotransmitter-related pathways involving serotonin, GABA, and tryptophan metabolism [56]. Preclinical studies further suggest that polyphenols such as curcumin, resveratrol, quercetin, epigallocatechin gallate (EGCG), kaempferol, and anthocyanins can reduce

neuroinflammation, support blood-brain barrier integrity, and improve behavioral or cognitive outcomes by acting through the microbiota-gut-brain axis [56]. Although IBS-specific clinical data remain limited, these mechanisms closely overlap with core IBS pathophysiology, supporting polyphenols as plausible adjunctive nutraceuticals for future gut-brain-targeted interventions.

Table 1: Representative dietary polyphenols implicated in gut-brain axis modulation.

Polyphenol (Class)	Dietary Source	Gut Microbiota Effect		Proposed	GBA-
				Related Mechanism	
Curcumin (curcuminoid)	Turmeric (Curcuma longa)	Increases Lactobacillus and Bifidobacterium; raises butyrate-producing taxa		Anti-inflammatory; raises hippocampal BDNF and serotonin; supports barrier integrity	r
Resveratrol (stilbene)	Grapes, red wine, berries	Shifts Firmicutes-to-Bacteroidetes ratio; supports SCFA-producing taxa		Reduces neuroinflammation; supports blood-brain barrier integrity	
Quercetin (flavonol)	Onions, apples, tea	Promotes Akkermansia muciniphila abundance		Suppresses microglial NF-kB and NLRP3 inflammasome activation	
EGCG (flavan-3-ol/catechin)	Green tea	Enhances colonic bioactive metabolites	Bifidobacterium; conversion to valerolactone	Antioxidant and anti-inflammatory	metab
				olite generation	
Kaempferol	Kale, broccoli,	Modulates barrier-associated		Neuroprotective; supports tight-	

Table 2: Dietary Polyphenols, Their Effects on Gut Microbiota, and Proposed Mechanisms in the Gut–Brain Axis (GBA)

Polyphenol (Class)	Dietary Source	Gut Microbiota Effect	Proposed Mechanism	GBA-Related
(flavonol)	berries	microbial populations	junction protein expression	
Anthocyanins (flavonoid)	Berries, dark grapes, red cabbage	Increases SCFA-producing taxa; lowers pathogenic bacterial load	Reduces oxidative stress; supports cognitive and behavioral outcomes	

2. Marine-Based Nutraceuticals

2.1 Omega-3 Fatty Acids

Omega-3 polyunsaturated fatty acids, primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), derived from fatty fish, krill, and algal sources, constitute essential components of neuronal membrane phospholipids and exert profound anti-inflammatory effects within the GBA [29]. EPA and DHA modulate eicosanoid production, reducing pro-inflammatory mediators while promoting specialized pro-resolving lipid mediators including resolvins and protectins [30]. These fatty acids preserve intestinal barrier integrity by maintaining tight junction protein expression and reducing lipopolysaccharide translocation, while simultaneously supporting CNS function through enhancement of neurogenesis, synaptic plasticity, and neurotransmission [31]. Additionally, omega-3 fatty acids influence gut microbiota composition, promoting beneficial bacterial populations including *Bifidobacterium* and *Akkermansia muciniphila* [32].

2.2 Seaweed-Derived Bioactive Compounds

Marine algae and seaweeds represent rich sources of bioactive compounds with GBA-modulating potential. Fucoidan, a sulfated polysaccharide abundant in brown algae including *Fucus vesiculosus* and *Undaria pinnatifida*, demonstrates antioxidant, anti-inflammatory, and anti-apoptotic activities that may protect intestinal epithelial cells and modulate neuroinflammation [33]. Fucoxanthin, a carotenoid pigment found in brown seaweeds, exhibits neuroprotective properties and supports autophagy and mitochondrial function [34]. Marine bioactive peptides derived from enzymatic hydrolysis of seaweed proteins show promise in modulating neuroinflammation and oxidative stress, though human clinical evidence remains limited [35]. Ulvan, derived from green algae, possesses immunomodulatory and antioxidant properties relevant to intestinal health [36].

3. Mineral-Based Nutraceuticals

Micronutrient deficiencies are prevalent among IBS patients, with systematic reviews documenting inadequate intake of vitamins A, B2, B9, B12, calcium, and zinc compared to healthy controls and dietary reference values [37]. Vitamin D deficiency occurs in 70-80% of IBS patients and correlates significantly with symptom severity and quality of life impairment [38]. Supplementation trials demonstrate that vitamin D reduces inflammatory markers including IL-17 and TNF-alpha while improving IBS symptom severity scores and quality of life measures [39]. The mechanisms involve vitamin D receptor-mediated modulation of intestinal barrier function, immune regulation, and antimicrobial peptide production.

Magnesium plays essential roles in smooth muscle relaxation and nervous system regulation, making it particularly relevant for IBS management. Magnesium deficiency exacerbates gut dysmotility and stress responses, while supplementation regulates bowel function by relaxing digestive tract smooth muscles and modulating the stress response through the HPA axis [40]. Zinc supports intestinal epithelial integrity, wound healing, and immune function, with dietary intake significantly lower in IBS patients compared to healthy controls [41]. Zinc and magnesium demonstrate complementary actions in addressing both gut-driven inflammation and stress-driven symptom flares [42].

4. Animal-Based Nutraceuticals

Bovine colostrum, the nutrient-rich first milk produced post-parturition, contains a complex mixture of bioactive components including immunoglobulins (particularly IgG), lactoferrin, growth factors (IGF-1, TGF-beta, EGF), oligosaccharides, and bioactive peptides [43]. These components synergistically strengthen intestinal mucosal barriers, modulate gut-associated immunity, and neutralize endotoxins. Clinical studies demonstrate that bovine colostrum reduces intestinal permeability markers including stool zonulin and circulating bacterial DNA, indicating reduced microbial translocation [44]. For IBS specifically, colostrum's barrier-restoring and anti-endotoxin effects address the low-grade inflammation and epithelial leak characteristic of the condition, though targeted IBS trials remain limited [45].

L-glutamine, the most abundant free amino acid in the body, serves as the preferred fuel source for enterocytes and colonocytes and plays a critical role in maintaining intestinal barrier integrity [46]. Clinical evidence demonstrates that glutamine supplementation reduces intestinal permeability, preserves tight junction protein expression, and attenuates

inflammatory responses across diverse patient populations [47]. In IBS, glutamine represents a conditionally essential nutrient during periods of physiological stress, with supplementation potentially addressing the increased intestinal permeability and immune activation observed in post-infectious IBS subtypes [48].

5. Market Availability and Commercial Formulations

The global IBS support supplements market has experienced substantial growth, driven by increasing consumer preference for natural therapeutic approaches and expanding scientific validation of nutraceutical efficacy. Major market players including Align (Procter & Gamble), Culturelle (i-Health), and VSL#3 (Sigma-Tau Pharmaceuticals) have developed proprietary probiotic formulations with strain-specific clinical evidence [49]. Align contains *Bifidobacterium longum* 35624, one of the most extensively studied probiotic strains for IBS, demonstrating significant improvement in abdominal pain and bloating [50]. Culturelle features *Lactobacillus rhamnosus* GG with documented benefits for gastrointestinal comfort and immune function.

Herbal formulations including Iberogast (STW 5), a multi-herbal preparation containing bitter candytuft, chamomile, peppermint, and other botanical extracts, demonstrate efficacy in functional dyspepsia and IBS through multimodal mechanisms involving spasmolytic, anti-inflammatory, and prokinetic effects [51]. Commercial berberine supplements typically provide 500 mg per capsule, often combined with bioavailability enhancers such as piperine. Marine-derived omega-3 supplements range from 1000-3000 mg combined EPA/DHA daily, with enteric-coated formulations improving gastrointestinal tolerability [52].

Table 3: Major Categories, Sources, Bioactive Compounds, and Commercial Examples of Natural Health Products

Category	Source	Key Compounds		Commercial Examples	
Plant-Based	Fruits, vegetables, herbs	Probiotics, berberine, ginger	prebiotics, curcumin,	Align, Iberogast, capsules	Culturelle, turmeric
Marine-Based	Fish, seaweed, algae	Omega-3 (EPA/DHA), fucoidan, fucoxanthin		Nordic Naturals, krill oil supplements	
Mineral-Based	Rocks, soil, water	Magnesium, zinc, vitamin D		Mg glycinate, picolinate, supplements	Zn D3
Category	Source	Key Compounds		Commercial Examples	
		glutamine, lactoferrin		glutamine capsules	
Animal-Based	Dairy, meat	Bovine colostrum, L-		Colostrum	powder,

Conclusion and Future Directions

Natural-based nutraceuticals targeting the GBA represent a promising therapeutic frontier for IBS management, offering multimodal mechanisms that address the complex pathophysiology of this disorder. Plant-derived probiotics, prebiotics, and herbal compounds demonstrate the strongest clinical evidence, with marine, mineral, and animal-derived supplements providing complementary benefits. The convergence of microbiota modulation, barrier restoration, anti-inflammatory activity, and neuromodulation positions these compounds as valuable components of integrated IBS management strategies. Future research should prioritize large-scale randomized controlled trials with standardized outcome measures, stratification by IBS phenotype, and integration of biomarkers to identify responder populations and optimize therapeutic protocols [53]. Personalized nutraceutical approaches based on individual microbiome profiles and nutritional status may ultimately enhance treatment precision and improve patient outcomes in IBS management.

References

[1] Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-721.

[2] Canavan C, West J, Card T. The economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014;40(9):1023-1034.

[3] Bhattarai Y, Kashyap PC. Mast cells as sensor and effector in bidirectional gut-brain communication. Curr Opin Pharmacol. 2021;59:50-58.

[4] Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203-209.

[5] Furness JB, Callaghan BP, Rivera LR, Cho HJ. The enteric nervous system and gastrointestinal innervation:

- integrated local and central control. *Adv Exp Med Biol.* 2014;817:39-71.
- [6] Fond G, Loundou A, Hamdani N, et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. *Eur Arch Psychiatry Clin Neurosci.* 2014;264(8):651-660.
 - [7] Ford AC, Moayyedi P, Chey WD, et al. American College of Gastroenterology monograph on management of irritable bowel syndrome. *Am J Gastroenterol.* 2018;113(Suppl 2):1-18.
 - [8] Ursell LK, Haider HJ, Van Treuren W, et al. The intestinal metabolome: an intersection between microbiota and host. *Gastroenterology.* 2014;146(6):1470-1476.
 - [9] Bonaz B, Bazin T, Pellissier S. The vagus nerve at the interface of the microbiota-gut-brain axis. *Front Neurosci.* 2018;12:49.
 - [10] Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. *Gastroenterology.* 2007;132(1):397-414.
 - [11] Jenkins TA, Nguyen JCD, Polglaze KE, Bertrand PP. Influence of tryptophan and serotonin on mood and cognition with a possible role of the gut-brain axis. *Nutrients.* 2016;8(1):56.
 - [12] Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. *Front Endocrinol.* 2020;11:25.
 - [13] Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. *J Nutr.* 2009;139(9):1619-1625.
 - [14] Zhu MT, et al. Therapeutic potential of short-chain fatty acids in gastrointestinal diseases. *MedComm.* 2025;5(3):19.
 - [15] Barbosa JJV, et al. Probiotics in irritable bowel syndrome: an umbrella review of 27 systematic reviews. *Nutrients.* 2025;17(9):1551.
 - [16] Xie P, Luo M, Deng X, et al. Outcome-specific efficacy of different probiotic strains in IBS: a network meta-analysis. *Nutrients.* 2023;15:3856.
 - [17] Cryan JF, O'Riordan KJ, Cowan CSM, et al. The microbiota-gut-brain axis. *Physiol Rev.* 2019;99(4):1877-2013.
 - [18] Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nat Rev Gastroenterol Hepatol.* 2017;14(8):491-502.
 - [19] Giannini EG, Mansi C, Dulbecco P, Savarino V. Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. *Nutrition.* 2006;22(3):334-342.
 - [20] Pandey KR, Naik SR, Vakil BV. Probiotics, prebiotics and synbiotics: a review. *J Food Sci Technol.* 2015;52(12):7577-7587.
 - [21] Cicero AFG, Baggioni A. Berberine and its role in chronic disease. *Adv Exp Med Biol.* 2016;928:27-45.
 - [22] Li L, et al. Berberine nanoparticles with baicalin for IBS-D treatment. *Front Pharmacol.* 2020;11:560.
 - [23] Cao S, et al. Berberine in bowel health: anti-inflammatory and gut microbiota modulatory effects. *Int J Mol Sci.* 2025;26(24):12021.
 - [24] Zhu X, et al. The effect of curcumin on the gut-brain axis. *J Nutr Biochem.* 2019;72:108231.
 - [25] Ng QX, et al. A meta-analysis of the clinical use of curcumin for irritable bowel syndrome. *J Clin Med.* 2018;7(10):298.
 - [26] Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. *J Altern Complement Med.* 2004;10(6):1015-1018.
 - [27] Prasad S, Tyagi AK. Ginger and its constituents: role in prevention and treatment of gastrointestinal cancer. *Ginger.* 2016:239-255.
 - [28] Nikkhah Bodagh M, Maleki I, Hekmatdoost A. Ginger in gastrointestinal disorders: a systematic review of clinical trials. *Food Sci Nutr.* 2019;7(1):96-108.

- [29] Lauritano EC, et al. Molecular mechanisms linking omega-3 fatty acids and the gut-brain axis. *Int J Mol Sci.* 2024;25(22):12345.
- Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. *Biochem Soc Trans.* 2017;45(5):1105-1115.
- [30] Bazinet RP, Laye S. Polyunsaturated fatty acids and their metabolites in brain function and disease. *Nat Rev Neurosci.* 2014;15(12):771-785.
- [31] Watson H, et al. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. *Gut.* 2018;67(11):1974-1983.
- [32] Liu J, et al. Neurological benefits of seaweed-derived compounds. *Mar Drugs.* 2025;23(4):234.
- [33] Peng J, et al. Fucoxanthin and its metabolite fucoxanthinol in cancer prevention and treatment. *Mar Drugs.* 2021;19(3):142.
- [34] Harnedy PA, FitzGerald RJ. Bioactive peptides from marine processing waste and shellfish: a review. *J Funct Foods.* 2012;4(1):6-24.
- [35] Kraan S. Algal polysaccharides, novel applications and outlook. In: *Carbohydrates.* 2012:345-368.
- [36] Khayyat-zadeh SS, et al. Association between IBS and micronutrients: a systematic review. *J Gastroenterol Hepatol.* 2022;37(9):1658-1667.
- [37] Abbasnezhad Z, et al. Vitamin D status in irritable bowel syndrome. *Gastroenterol Hepatol Bed Bench.* 2019;12(1):1-6.
- [38] Amani R, et al. Vitamin D supplementation effects on IL-17 and TNF-alpha in IBS. *Neurogastroenterol Motil.* 2018;30(12):e13491.
- [39] Tarleton EK, Littenberg B. Magnesium intake and depression in adults. *J Am Board Fam Med.* 2015;28(2):249-256.
- [40] Bahrami A, et al. Zinc intake in adolescent girls with IBS. *Biol Trace Elem Res.* 2019;191(2):232-238.
- [41] Wearefeel. Best vitamins and minerals for IBS and IBD. *Nutr Rev.* 2025.
- [42] Godhia ML, Patel N. Colostrum: its composition, benefits as a nutraceutical: a review. *Curr Res Nutr Food Sci.* 2013;1(1):37-47.
- [43] Marchbank T, et al. The nutraceutical bovine colostrum truncates the increase in gut permeability caused by heavy exercise in athletes. *Am J Physiol Gastrointest Liver Physiol.* 2011;300(3):G477-G484.
- [44] An MJ, et al. Clinical applications of bovine colostrum in GI disorders. *J Clin Med.* 2025;14(8):2674.
- [45] Rao R, Samak G. Role of glutamine in protection of intestinal epithelial tight junctions. *J Epithel Biol Pharmacol.* 2012;5(Suppl 1):47-54.
- [46] Kim MH, Kim H. The roles of glutamine in the intestine and its implication in intestinal diseases. *Int J Mol Sci.* 2017;18(5):1051.
- [47] Bertrand J, et al. L-glutamine restores tight junction protein expression in experimental colitis. *J Nutr Biochem.* 2015;26(12):1717-1723.
- [48] MarketIntel. IBS support supplements market research report 2033. 2025.
- [49] Whorwell PJ, et al. Efficacy of an encapsulated probiotic *Bifidobacterium infantis* 35624 in women with irritable bowel syndrome. *Am J Gastroenterol.* 2006;101(7):1581-1590.
- [50] Madisch A, et al. Treatment of IBS with herbal preparations: results of a double-blind, randomized, placebo-controlled trial. *Aliment Pharmacol Ther.* 2004;19(3):271-279.
- [51] Costigan T. Enteric-coated omega-3 supplements for GI tolerability. *Gastroenterol Today.* 2024.
- [52] Tajbakhsh A, et al. Modulatory effects of phytochemicals on gut-brain axis. *Phytother Res.* 2024;38(7):3124-3145.
- [53] Serra D, Almeida LM, Dinis TCP. Dietary polyphenols: a novel strategy to modulate microbiota-gut-brain axis. *Trends Food Sci Technol.* 2018;78:224-233.
- [54] Domínguez-López I, López-Yerena A, Vallverdú-Queralt A, Pallàs M, Lamuela-Raventós RM, Pérez M.

From the gut to the brain: the long journey of phenolic compounds with neurocognitive effects. *Nutr Rev.* 2025;83(2):e533-e546.

- [55] Wang Z, Ba S, Li M, Wei Y, Wang Y, Mao J, Xiang Y, Qin D, Zeng C. Targeting the gut microbiota: mechanistic investigation of polyphenol modulation of the gut-brain axis in Alzheimer's disease. *Int J Mol Sci.* 2026;27(2):604.